10x Genomics Inc - Ordinary Shares - Class A
TXG
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
63.6% downsideOvervalued by 63.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.42 Billion |
|---|---|
| Enterprise Value | $5.04 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.35 |
| Beta | 2.04 |
| Outstanding Shares | 128,291,153 |
Return
| Return on Equity | -2.78% |
|---|---|
| Return on Assets | -2.23% |
| Return on Invested Capital | -3.53% |
Valuation & Multiples
| P/E Ratio | -251.35 |
|---|---|
| PEG | 413.44 |
| Price to Sales | 10.44 |
| Price to Book Ratio | 6.96 |
| Enterprise Value to Revenue | 7.89 |
| Enterprise Value to EBIT | -158.36 |
| Enterprise Value to Net Income | -223 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 6.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.15%▼ 98.35% |
|---|---|
| Total Invested | $7.57M▼ 99.71% |
| Investors Holding | 13▼ 325.00% |
ESG Score
No data
About 10x Genomics Inc
CEO: Serge Saxonov Relevant Senate Committees
The Labor-HHS subcommittee directly determines the exact annual budget for the NIH. Any fluctuations in this funding immediately impact the purchasing power of TXG's primary research customers.
This committee oversees the NIH and FDA. The NIH is the primary funder of TXG's academic customers, and the FDA determines the pathway for genomic tools to enter the clinical diagnostics market.
10x Genomics is heavily reliant on intellectual property and has been involved in extensive patent litigation; this committee oversees the laws and agencies (USPTO/DOJ) that govern these critical assets.